Evaluation of In-Vivo Bronchodilator Activity of Mono-Herbal Siddha Formulation Kanduparangi Chooranam (Pygmaeopremna Herbacea - Root Powder) by Egg Albumin-Induced Anaphylaxis in Guinea Pigs

Abstract

Monoherbal formulation, which is used in ancient Siddha medication, has an abundant variety of bioactive substances as primary and secondary metabolic products, which shows so many medicative activities including the bronchodilator effect. The bronchodilator activity of Kanduparangi chooranam (KC) was evaluated by using egg albumin-induced anaphylaxis in guinea pigs. Group I was administered 0.5% CMC (control), Group II: Mepyramine maleate (10 mg/kg= 0.1% Soln.) (Standard), Group III: Kanduparangi chooranam (100 mg/kg), Group IV: Kanduparangi chooranam (200 mg/kg). One and half hours later the animals were exposed to 0.2% histamine aerosol and time for p re-convulsive d yspnoea state (PCD) was noted for each animal. The endpoint for PCOD was determined from the time of aerosol exposure to the onset of dyspnea leading to the appearance of convulsions. The mono herbal drug significantly prohibited egg albumin-induced anaphylactic response and there is 0.00% mortality in the group treated with Siddha formulation Kanduparangi chooranam (200 mg/kg) against 70% mortality inthe control group (untreated group). The findings reveal protection against egg albumin-induced anaphylactic shock characterized by a decrease in intensity and delay in the development of symptoms of dyspnoea, asphyxia and collapse. In line with this notion, the bronchodilator effect of Kanduparangi chooranam may be due to the inhibition of the phenomenon of sensitization or the non-availability of antibodies on the mast cell surface. These results suggest that Kanduparangi chooranam has significant bronchodilator activity which is useful in the management of acute or chronic asthmatic conditions.